Liquid biopsy for glioblastoma diagnosis [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Liquid biopsy for glioblastoma diagnosis ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1fEDSjbVglh-tLEeWCHyGeKb8C6FwIgX4dWPcsPrsG1dLNgkrU/?limit=15&utm_campaign=pubmed-2&fc=20230212042828}}
----

----

[[Liquid biopsy]] is a [[minimally invasive]] diagnostic [[tool]] that involves the analysis of tumor-derived materials, such as DNA, RNA, or proteins, that circulate in the blood or other bodily fluids. While the liquid biopsy is a promising approach for cancer diagnosis, its use in the diagnosis of glioblastoma, a highly aggressive brain cancer, is still in the early stages of development. The challenges of detecting glioblastoma-associated biomarkers in the blood or cerebrospinal fluid, as well as the potential for false-positive or false-negative results, are still being addressed. However, research into the use of liquid biopsy for [[glioblastoma diagnosis]] is ongoing and may hold promise for improving the early detection and monitoring of this deadly disease.
----
Mathios et al. highlight the recent methodological improvements in the field of liquid biopsy technologies specifically for [[glioblastoma diagnosis]]. Although many retrospective and few prospective studies have been conducted to assess the utility of circulating biomarkers for the detection of brain tumors, none have yet moved forward to clinical implementation
((Mathios D, Phallen J. Circulating Biomarkers in Glioblastoma: Ready for Prime Time? Cancer J. 2021 Sep-Oct 01;27(5):404-409. doi: 10.1097/PPO.0000000000000541. PMID: 34570455.)).


----

[[Liquid biopsy]] can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of [[cancer]], measuring circulating tumor-derived [[nucleic acid]]s from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in [[glioblastoma]] as well
((Birkó Z, Nagy B, Klekner Á, Virga J. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy. Int J Mol Sci. 2020 Oct 12;21(20):7522. doi: 10.3390/ijms21207522. PMID: 33053907; PMCID: PMC7589793.)).
----
A number of circulating factors have been examined, including circulating tumor cells, cell-free DNA, [[microRNA]], exosomes, and proteins from both peripheral [[blood]] and [[cerebrospinal fluid]] with variable results
((Jones J, Nguyen H, Drummond K, Morokoff A. Circulating [[Biomarkers for Glioma]]: A Review. Neurosurgery. 2021 Feb 16;88(3):E221-E230. doi: 10.1093/neuros/nyaa540. PMID: 33442748.)).
----
It was feasible to measure [[Cell-free DNA]] concentration. Despite the limited [[cohort]] size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at [[progression]]
((Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study. Oncotarget. 2019 Jul 8;10(43):4397-4406. doi: 10.18632/oncotarget.27030. PMID: 31320993; PMCID: PMC6633897.))
----
[[Plasma]] [[cell-free DNA]] may be an effective prognostic tool and surrogate of tumor burden in newly diagnosed [[glioblastoma]]. Detection of somatic alterations in plasma is feasible when samples are obtained prior to initial surgical resection
((Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020 Jan 15;26(2):397-407. doi: 10.1158/1078-0432.CCR-19-2533. Epub 2019 Oct 30. PMID: 31666247; PMCID: PMC6980766.)).
----
It is a promising [[prognostic biomarker]] for [[IDH-wildtype glioblastoma]]. Plasma cfDNA can be obtained noninvasively and may enable more accurate estimates of [[survival]] and effective [[clinical trial]] stratification
((Bagley SJ, Till J, Abdalla A, Sangha HK, Yee SS, Freedman J, Black TA, Hussain J, Binder ZA, Brem S, Desai AS, O'Rourke DM, Long Q, Nabavizadeh SA, Carpenter EL. Association of plasma cell-free DNA with survival in patients with IDH-wildtype glioblastoma. Neurooncol Adv. 2021 Jan 16;3(1):vdab011. doi: 10.1093/noajnl/vdab011. PMID: 33615225; PMCID: PMC7883768.))





===== Cerebrospinal Fluid Liquid Biopsy for glioblastoma diagnosis =====

[[Cerebrospinal Fluid Liquid Biopsy for glioblastoma diagnosis]]